6533b837fe1ef96bd12a3275
RESEARCH PRODUCT
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
Alessandro VatrellaCorrado PelaiaEugenio GarofaloRosa TerraccianoMaria Teresa BuscetiGirolamo PelaiaCecilia CalabreseNicola Lombardosubject
Genetics and Molecular Biology (all)0301 basic medicineImmunology and Microbiology (all)lcsh:MedicineReview ArticleAntibodies Monoclonal HumanizedBiochemistryAntibodiesGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compoundTh2 Cells0302 clinical medicineReslizumabMonoclonalEosinophilicmedicineAnimalsHumansEosinophiliaHumanizedInterleukin 5AsthmaGeneral Immunology and Microbiologybusiness.industrylcsh:RInnate lymphoid cellGeneral Medicinemedicine.diseaseBenralizumabAsthmarespiratory tract diseasesBiological Therapy030104 developmental biology030228 respiratory systemchemistryImmunologyInterleukin-5medicine.symptombusinessMepolizumabAnimals; Antibodies Monoclonal Humanized; Asthma; Biological Therapy; Humans; Interleukin-5; Th2 Cells; Biochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugdescription
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma. In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-02-14 |